 |
PodcastDXAuthor: PodcastDX
PodcastDX is an interview based weekly series. Guests share experience based medical insight for our global audience. We have found that many people are looking for a platform, a way to share their voice and the story that their health journey has created. Each one is unique since even with the same diagnosis, symptoms and the way each person will react to a diagnosis, is different. Sharing what they have experienced and overcome is a powerful way our guests can teach others with similar ailments. Many of our guests are engaging in self-advocacy while navigating a health condition, many are complex and without a road-map to guide them along their journey they have developed their own. Sharing stories may help others avoid delays in diagnosis or treatment or just give hope to others that are listening. Sharing is empowering and has a healing quality of its own. Our podcast provides tips, hints, and support for common healthcare conditions. Our guests and our listeners are just like you- navigating the complex medical world. We hope to ease some tension we all face when confronted with a new diagnosis. We encourage anyone wanting to share their story with our listeners to email us at info@PodcastDX.com Language: en Genres: Alternative Health, Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Promising New Cancer Screening Methods
Episode 8
Monday, 9 February, 2026
Promising new cancer screening methods are pivoting toward multi-cancer early detection (MCED) blood tests (liquid biopsies) and AI-enhanced imaging, which aim to detect multiple cancer types from a single, non-invasive sample, often before symptoms arise. These technologies, including the Galleri test and Novelna's protein-based tests, analyze DNA, proteins, or methylation patterns to identify cancer signals. Multi-Cancer Early Detection (MCED) Blood Tests: These tests, often called liquid biopsies, detect DNA or proteins shed by cancer cells into the bloodstream, identifying early-stage cancers (e.g., ovarian, pancreatic) that lack standard screening protocols. Galleri Test: Analyzes chemical methylation patterns to detect over 50 types of cancer, with the potential to indicate the cancer's origin in the body. Novelna's Test: An experimental test analyzing protein signatures, showing high accuracy in identifying 18 early-stage cancers, including 93% of stage 1 cancers in men. TriOx Test: A new, Oxford-developed test showing high sensitivity in detecting trace cancer DNA. AI and Machine Learning in Screening: AI is enhancing existing imaging techniques (e.g., mammography) to improve accuracy and efficiency in reading scans, reducing false positives. Other Liquid Biopsies: Research into analyzing blood, breath, and urine for early signs of cancer, offering a less invasive alternative to tissue biopsies. While offering immense promise for reducing cancer mortality, many of these technologies, including MCED, are still in research or early implementation phases, and they can produce false positives.
